Jonas Bergh
Jonas Bergh is a breast oncologist and long-standing leader of Swedish and European breast cancer trials.
Jonas Bergh leads breast cancer research at Karolinska and has co-led trials of dose-dense chemotherapy and tailored adjuvant therapy within the Swedish Breast Cancer Group and the Early Breast Cancer Trialists' Collaborative Group.
Pages like this
not linked directly; found by shared links- PersonJame Abraham
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- PersonShinji Ohno
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- PersonClifford A. Hudis
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- PersonYeon Hee Park
Shares KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- ProductPegulicianine
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- IdeaPublic country dashboards for the three WHO breast cancer targets
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- PersonThomas Bachelot
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- IdeaOne-stop breast clinics: imaging, biopsy and a preliminary answer in a single visit
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.